Medical therapy in adults with fibrous dysplasia of bone

Journal of Bone and Mineral Research

Volumn 22, Issue SUPPL. 2, 2007, Pages

  Chapurlat, Roland D ^a,b  

^a UNIVERSITÉ LYON 1   (France)

^b EDOUARD HERRIOT HOSPITAL   (France)

Author keywords

Bisphosphonates; Fibrous dysplasia of bone; McCune Albright syndrome; Pamidronate; Zoledronate

Indexed keywords

ALENDRONIC ACID; BISPHOSPHONIC ACID DERIVATIVE; CALCIUM; PAMIDRONIC ACID; PHOSPHORUS; VITAMIN D; ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ARTICLE; BONE MALFORMATION; BONE MINERALIZATION; BONE PAIN; BONE RADIOGRAPHY; CALCIUM DEFICIENCY; CELL DIFFERENTIATION; CELL LINEAGE; CONTINUOUS INFUSION; DISEASE ASSOCIATION; DRUG SUBSTITUTION; FIBROUS DYSPLASIA; FRACTURE; HUMAN; LONG TERM CARE; MULTIPLE CYCLE TREATMENT; OSTEOBLAST; OSTEOCLAST; OSTEOLYSIS; OSTEOMALACIA; PHOSPHATE DEFICIENCY; RARE DISEASE; RICKETS; SECONDARY HYPERPARATHYROIDISM; SIDE EFFECT; TREATMENT OUTCOME; VEIN DISEASE; VENOUS IRRITATION; VITAMIN D DEFICIENCY; VITAMIN SUPPLEMENTATION; ADOLESCENT; ADULT; CHILD; FEMALE; INFANT; MALE; MIDDLE AGED; PRESCHOOL CHILD; RADIOGRAPHY; REVIEW;

ADOLESCENT; ADULT; CHILD; CHILD, PRESCHOOL; DIPHOSPHONATES; FEMALE; FIBROUS DYSPLASIA OF BONE; HUMANS; INFANT; MALE; MIDDLE AGED; TREATMENT OUTCOME; VITAMIN D;

EID: 34247873198     PISSN: 08840431     EISSN: None     Source Type: Journal    
DOI: 10.1359/JBMR.06S222     Document Type: Article

References (20)

1. Weinstein LS, Shenker A, Gejman PV, Merino MJ, Friedman E, Spiegel AM 1991 Activating mutations of the stimulatory G protein in the McCune-Albright syndrome. N Engl J Med 325:1688-1695.
2. Candeliere GA, Glorieux F, Prud'homme J, St Arnaud R 1995 Increased expression of the c-fos proto-oncogene in bone from patients with fibrous dysplasia. N Engl J Med 332:1546-1551.
3. Yamamoto T, Ozono K, Kasayama S, Yoh K, Hiroshima K, Takagi M, Matsumoto S, Michigami T, Yamaoka K, Kishimoto T, Okada S 1996 Increased IL-6 production by cells isolated from the fibrous bone dysplasia tissues in patients with McCune-Albright syndrome. J Clin Invest 98:30-35.
4. Riminucci M, Liu B, Corsi A, Shenker A, Spiegel AM, Gehron Robey P, Bianco P 1999 The histopathology of fibrous dysplasia of bone in patients with activating mutations of the Gs alpha gene: Site-specific patterns and recurrent histological hallmarks. J Pathol 187:249-258.
5. Riminucci M, Kuznetsov SA, Cherman N, Corsi A, Bianco P, Gehron Robey P 2003 Osteoclastogenesis in fibrous dysplasia of bone: In situ and in vitro analysis of IL-6 expression. Bone 33:434-442.
6. Liens D, Delmas PD, Meunier PJ 1994 Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. Lancet 343:953-954.
7. Reid IR, Nicholson GC, Weinstein RS, Hosking DJ, Cundy T, Kotowicz MA, Murphy WA, Yeap S, Dufresne S, Lombardi A, Musliner TA, Thompson DE, Yates AJ 1996 Biochemical and radiological improvement in Paget's disease of bone treated with alendronate: A randomized, placebo-controlled trial. Am J Med 101:341-348.
8. Corsi A, Collins MT, Riminucci M, Howell PGT, Boyde A, Gehron Robey P, Bianco P 2003 Osteomalacic and hyperparathyroid changes in fibrous dysplasia of bone: Core biopsy studies and clinical correlations. J Bone Miner Res 18:1235-1246.
9. Collins MT, Chebli C, Jones J, Kushner H, Consugar M, Rinaldo P, Wientroub S, Bianco P, Gehron Robey P 2001 Renal phosphate wasting in fibrous dysplasia of bone is part of a generalized renal tubular dysfunction similar to that seen in tumor-induced osteomalacia. J Bone Miner Res 16:806-813.
10. Chapurlat RD, Delmas PD, Liens D, Meunier PJ 1997 Long-term effects of intravenous pamidronate in fibrous dysplasia of bone. J Bone Miner Res 12:1746-1752.
11. Chapurlat RD, Hugueny P, Delmas PD, Meunier PJ 2004 Treatment of fibrous dysplasia of bone with intravenous pamidronate: Predictors of response to treatment and long-term effectiveness. Bone 35:235-242.
12. Chapurlat R, Meunier PJ 1999 The nonsurgical treatment of fibrous dysplasia. Rev Rhum Engl Ed 66:1-3.
13. Parisi MS, Oliveri B, Mautalen CA 2003 Effect of intravenous pamidronate on bone markers and local bone mineral density in fibrous dysplasia of bone. Bone 33:582-588.
14. Weinstein RS 1997 Long-term aminobisphosphonate treatment of fibrous dysplasia: Spectacular increase in bone density. J Bone Miner Res 12:1314-1315.
15. Kitagawa Y, Tamai K, Ito H 2004 Oral alendronate treatment for polyostotic fibrous dysplasia: A case report. J Orthop Sci 9:521-525.
16. Lane JM, Khan SF, O'Connor WJ, Nydick M, Hommen JP, Schneider R, Tomin E, Brand J, Curtin J 2001 Bisphosphonate therapy in fibrous dysplasia. Clin Orthop Rel Res 382:6-12.
17. Bianco P, Riminucci M, Majolagbe A, Kuznetsov SA, Collins MT, Mankani MH, Corsi A, Bone HG, Wientroub S, Spiegel AM, Fisher LW, Gehron Robey P 2000 Mutations of the GNAS1 gene, stromal cell dysfunction, and ostemalacic changes in non-McCune-Albright fibrous dysplasia of bone. J Bone Miner Res 15:120-128.
18. Leet AI, Chebli C, Kushner H, Chen CC, Kelly MH, Brillante BA, Robey PG, Bianco P, Wientroub S, Collins MT 2004 Fracture incidence in polyostotic fibrous dysplasia and the McCune-Albright syndrome. J Bone Miner Res 19:571-577.
19. Plotkin H, Rauch F, Zeitlin L, Munns C, Travers R, Glorieux FH 2003 Effect of pamidronate treatment in children with polyostotic fibrous dysplasia of bone. J Clin Endocrinol Metab 88:4569-4575.
20. Collins MT, Kushner H, Reynolds JC, Chebli C, Kelly MH, Gupta A, Brillante B, Leet AI, Riminucci M, Robey PG, Bianco P, Wientroub S, Chen CC 2005 An instrument to measure skeletal burden and predict functional outcome in fibrous dysplasia of bone. J Bone Miner Res 20:219-226.